1.RANTES, MCP-1, CCR2, CCR5, CXCR1 and CXCR4 Gene Polymorphisms are not Associated with the Outcome of Hepatitis B Virus Infection: Results from a Large Scale Single Ethnic Population.
Jae Youn CHEONG ; Sung Won CHO ; Jeong Young CHOI ; Jung A LEE ; Min Ho KIM ; Jong Eun LEE ; Ki Baik HAHM ; Jin Hong KIM
Journal of Korean Medical Science 2007;22(3):529-535
Recovery from hepatitis B virus (HBV) infection depends on the cellular immune responses. Chemokines and their receptors play significant roles in immune defense. This study was undertaken to investigate the association between HBV infection and single nucleotide polymorphisms (SNPs) of genes for the chemokines and their receptors. Between March 2002 and February 2004, a total of 957 single ethnic Korean patients were enrolled into two different groups; "HBV clearance group" (n=350), who have recovered from HBV infection, and "HBV persistence group" (n=607), who were repeatedly HBsAg-positive. The HBV persistence group was subdivided into "inactive carrier" and "HBV progression group (chronic hepatitis and cirrhosis)". We assessed polymorphisms in regulated and normal T-cell expressed and secreted (RANTES) at position -403, monocyte chemoattractant protein-1 (MCP-1) at position -2518, CCR2 V64I, CCR5 -2459, CXCR1 S276T and CXCR4 I138I using single primer extension assay. Genotype distributions of the "HBV clearance versus persistence group" and "inactive carrier versus HBV progression group" were compared. On the basis of unconditional logistic regression analysis with adjustment for age and sex, no statistically significant association with susceptibility to persistent HBV infection was observed with RANTES -403, MCP-1 -2518, CCR2 V64I, CCR5 -2459, CXCR1 S276T, and CXCR4 I138I polymorphisms. In addition, no association of analyzed SNPs with HBV disease progression was found.
Chemokine CCL2/*genetics
;
Chemokine CCL5/*genetics
;
Disease Progression
;
Genotype
;
Hepatitis B/ethnology/*genetics/*therapy
;
Hepatitis B virus/metabolism
;
Humans
;
Korea
;
*Polymorphism, Genetic
;
Receptors, CCR2
;
Receptors, CCR5/*genetics
;
Receptors, CXCR4/*genetics
;
Receptors, Chemokine/*genetics
;
Receptors, Interleukin-8A/*genetics
;
Regression Analysis
;
Treatment Outcome
2.Lamivudine Therapy for Korean Children with Chronic Hepatitis B.
Hong KOH ; Seoung Yon BAEK ; Ki Sup CHUNG
Yonsei Medical Journal 2007;48(6):927-933
PURPOSE: Lamivudine is known to be very effective in suppressing hepatitis B virus replication and virus induced necroinflammation. The aim of this study was to evaluate lamivudine therapy efficacy, predictive factors, breakthrough, prevalence of YMDD mutation, and relapse rate in Korean children with chronic hepatitis B. MATERIALS AND METHODS: Between August 1999 and February 2005, 60 children on lamivudine therapy for chronic hepatitis B were enrolled. Treatment response was defined as alanine aminotransferase (ALT) normalization, and HBeAg and HBV-DNA disappearance. RESULTS: Seroconversion rates of HBeAg and HBV-DNA were 42% and 53%, respectively, and ALT normalization rate was 88%. Seroconversion rates of HBeAg (60.0%) and anti-HBe (60.0%) were higher in patients younger than 6 years. Seroconversion rate of HBV-DNA (68.4%) and normalization rate of serum ALT (94.7%) were highest in patients between 6 and 12 years. Seroconversion rates of all HBV markers were lowest in patients older than 12 years. Predicted 3 year cumulative seroconversion rates, were 70%, 68% for HBeAg, HBV-DNA, respectively. These were calculated by Kaplan-Meier method. Cox proportional hazard regression model showed that pre-treatment ALT was a positive predictive factor for seroconversion of HBeAg and HBV-DNA. Breakthrough phenomenon was noted in 6 patients, and 3 had a YMDD mutation. CONCLUSION: Lamivudine therapy had a significant effect on HBeAg seroconversion and HBV-DNA disappearance, and ALT normalization for Korean children with chronic hepatitis B.
Adolescent
;
Adult
;
Age Factors
;
Alanine Transaminase/blood
;
Anti-HIV Agents/therapeutic use
;
*Asian Continental Ancestry Group
;
Child
;
Cohort Studies
;
DNA, Viral/blood
;
Female
;
Hepatitis B e Antigens/blood
;
Hepatitis B virus/*drug effects/genetics/immunology
;
Hepatitis B, Chronic/blood/*drug therapy/ethnology
;
Humans
;
Korea
;
Lamivudine/*therapeutic use
;
Male
;
Sex Factors
;
Treatment Outcome